Low in vitro resistances to 5 fluorocytosine in Candida and Cryptococcus neoformans isolates from Chile and Spain

被引：0
|
作者：
Torres-Rodríguez, JM [1 ]
Morera, Y [1 ]
Silva, V [1 ]
Díaz, MC [1 ]
机构：
[1] Univ Autonoma Barcelona, Fac Med, IMAS, IMIM,GREMEC, E-08193 Barcelona, Spain
来源：
TRENDS IN MEDICAL MYCOLOGY | 2003年
关键词：
D O I：
暂无
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Minimal Inhibitory Concentrations to 5-fluorocytosine (FC) of 89 isolates of Candida sp and I I of Cryptococcus neoformans were determinate using the standardised microbroth method M27-A (NCCLS). Only one of 63 isolates of C albicans was resistant to FC. C krusei showed the lowest susceptibility with a geometric mean of 9.2 mug/ml (MIC50% 8 mug/ml), meanwhile the other species were full susceptible (MIC less than or equal to 0.125 mug/ml) No resistances were found in C. neoformans (MIC 50% = 4 mug/ml). Yeasts isolates from Chile and Spain where the clinical use of FC is uncommon are exceptional, except with C. krusei.
引用
收藏
页码：159 / 163
页数：5
相关论文
共 50 条
  • [41] Cryptococcus neoformans and Cryptococcus gattii clinical isolates from Thailand display diverse phenotypic interactions with macrophages
    Hansakon, Adithap
    Mutthakalin, Putthiphak
    Ngamskulrungroj, Popchai
    Chayakulkeeree, Methee
    Angkasekwinai, Pornpimon
    VIRULENCE, 2019, 10 (01) : 26 - 36
  • [42] In vitro activity of voriconazole and amphotericin B against Candida albicans, Candida krusei, and Cryptococcus neoformans in human cerebrospinal fluid
    al Jalali, Valentin
    Sauermann, Robert
    Eberl, Sabine
    Zeitlinger, Markus
    INFECTION, 2019, 47 (04) : 565 - 570
  • [43] In vitro activity of voriconazole and amphotericin B against Candida albicans, Candida krusei, and Cryptococcus neoformans in human cerebrospinal fluid
    Valentin al Jalali
    Robert Sauermann
    Sabine Eberl
    Markus Zeitlinger
    Infection, 2019, 47 : 565 - 570
  • [44] PIGMENT FORMATION FOR DIFFERENTIATING CRYPTOCOCCUS-NEOFORMANS FROM CANDIDA-ALBICANS
    KORTH, H
    APPLIED MICROBIOLOGY, 1971, 21 (03) : 541 - &
  • [45] Molecular typing of clinical isolates of Cryptococcus neoformans/Cryptococcus gattii species complex from Northeast Mexico
    Gonzalez, Gloria M.
    Casillas-Vega, Nestor
    Garza-Gonzalez, Elvira
    Hernandez-Bello, Romel
    Rivera, Gildardo
    Rodriguez, Jesus Ancer
    Bocanegra-Garcia, Virgilio
    FOLIA MICROBIOLOGICA, 2016, 61 (01) : 51 - 56
  • [46] In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans
    Yamazumi, T
    Pfaller, MA
    Messer, SA
    Houston, A
    Hollis, RJ
    Jones, RN
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (10) : 2883 - 2886
  • [47] Serial isolates of Cryptococcus neoformans from patients with AIDS differ in virulence for mice
    Fries, BC
    Casadevall, A
    JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (06): : 1761 - 1766
  • [48] Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates:: April 2000 to March 2002
    Sar, B
    Monchy, D
    Vann, M
    Keo, C
    Sarthou, JL
    Buisson, Y
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (02) : 563 - 565
  • [49] Genetic mutations in Cryptococcus neoformans pyrimidine salvage pathway enzymes contribute to reduced susceptibility against 5-fluorocytosine
    Fatima Zohra Delma
    Dong-Hoon Yang
    Alfredo Cabrera-Orefice
    Jordy Coolen
    Abdullah M. S. Al-Hatmi
    Sarah A. Ahmed
    Willem J. G. Melchers
    Yun C. Chang
    Kyung J. Kwon-Chung
    Sybren de Hoog
    Paul E. Verweij
    Jochem B. Buil
    npj Antimicrobials and Resistance, 2 (1):
  • [50] Antifungal susceptibility of cryptococcus neoformans clinical isolates from different cities of Argentina
    Theill, L.
    Frola, C.
    Leonardelli, F.
    Guelfand, L.
    Macedo, D.
    Cabeza, M.
    Dudiuk, C.
    Garcia-Effron, G.
    Gamarra, M. S.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 73 : 275 - 275
12345